NanoPilot Platform Development
Extrahepatic Nucleic Acid Delivery
Key Facts
About Hone Bio
Hone Bio is a VC-backed, pre-clinical biotech tackling a fundamental limitation in lipid nanoparticle (LNP) drug delivery: inherent liver accumulation. The company's proprietary NanoPilot technology is a membrane-anchored antibody platform that actively blocks liver uptake while simultaneously directing LNPs to desired target cells via a modular targeting domain. This dual-function technology, which can be applied to standard LNPs in a simple 10-minute process, has the potential to expand the therapeutic application of mRNA, DNA, and other nucleic acid payloads to treat diseases in tissues like the lungs, brain, and immune cells. Hone Bio is part of the Science Creates ecosystem in Bristol and is advancing its platform through preclinical validation.
View full company profile